Alirocumab, the first PCSK-9 inhibitor approved by the FDA, is indicated for use in patients with familial hypercholesterolemia or those who require additional lowering of LDL cholesterol (Merćep et al., 2022). This evidence concerns the gene PCSK9 and familial hypercholesterolemia.